Transasia Group’s acquisition of Drewmarks the entry in the fast growing segment of diabetes management worldwide.It would benefit with the capabilities to offer proprietary Liquid Chromatography based Glycated hemoglobin analyzers and reagents to the laboratories worldwide. Glycated hemoglobin analysis by Liquid Chromatography is the method of choice in monitoring long term glycemic control in diabetics.
JAS Diagnostics Inc. is a manufacturer of clinical chemistry reagents. It supplies chemistry reagents that it has developed through its own indigenous R&D. It offers solutions with excellent stability in different formats of systems packs, liquid reagents and powder reagents.
According to sources, diabetes affects an estimated 250 million people worldwide with nearly 60% residing in India and China alone. An estimated 90 million people are affected in China followed by 60 million in India and 25 million people are affected in North America signalling a huge opportunity and the strategic nature of this acquisition.
Mr. Suresh Vazirani, Chairman and Managing Director, Transasia Bio-Medicals Ltd, stated that “The acquisition was a natural consequence of its focus on the challenges posed by the vast and fast growing diabetes monitoring segment.” He further added, “It is also to address the lack of quality solutions and supply options in India specifically and worldwide in the monitoring of long term glycemic control.”
Transasia is already a leading player in the field of autoimmune and Infectious diseases testing in North America with proprietary Mago platform and Immunosimplicity range of Immunoassays. With this acquisition, Transasiawill also foray in the lucrative physician/doctor’
The company has laid out plans to expand its markets for existing range of diabetes management, Hematology and Clinical Chemistry in the rest of the world, leveraging its direct presence in USA, Italy, Eastern Europe, Russian federation, Turkey and its distribution partners in 90 countries worldwide. Transasia plans to offer range of automated solutions in Clinical Chemistry in the North American market.
With this strategic acquisition, Transasia, has deftly complimented and combined the innovative and advanced products development capability of Drew with the marketing and distribution expertise of Transasia. Transasia has already started mapping the future developmental goals for newer more advanced analyzers in Diabetes, Hematology and Clinical Chemistry with the enhanced developmental and intellectual capital from the current acquisition.
About Transasia Bio-Medicals Ltd
Incepted in the year 1979, Transasia Bio-Medicals Ltd., is headquartered in Mumbai, India. It is India’s largest In Vitro Diagnostics Company and offers solutions and products in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Electrophoresis, Molecular Diagnostics, Diabetes Management and Microbiology.
Transasia is a part of the global Erba Mannheim GmbH Group. The Erba Diagnostics Group has spread its footprint across USA, Europe, Turkey and Eastern Europe & Russia, by means of various acquisitions – Erba Lachema s.r.o., Lachema International, IVAX Diagnostics, Inc., Diamedix Biologicals, S.r.l., ImmunoVision, Inc. and Erba Diasis Diagnostik Sistemler.
Transasia manufactures and markets equipments and reagents, with an impressive install base of around 30,000 equipments across India. Transasia also exports to more than 90 countries worldwide. The vast network of more than 150 service engineers, 350+ Sales and Marketing Team, 14 zonal offices, and 300+ Distributors allows us to reach out to customers across the length and breadth of the country. Alliances with international partners like Sysmex Corporation Japan, Wako Japan, Medica USA, Diesse Italy, IMMCO USA, Vircell Spain, Helena Biosciences UK, Genprobe USA, have ensured that cutting edge technology and solutions can be brought to India. (www.transasia.co.in )